88 related articles for article (PubMed ID: 20828111)
21. Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone.
Kung PP; Huang B; Zhang G; Zhou JZ; Wang J; Digits JA; Skaptason J; Yamazaki S; Neul D; Zientek M; Elleraas J; Mehta P; Yin MJ; Hickey MJ; Gajiwala KS; Rodgers C; Davies JF; Gehring MR
J Med Chem; 2010 Jan; 53(1):499-503. PubMed ID: 19908836
[TBL] [Abstract][Full Text] [Related]
22. Asymmetric synthesis of pochonin E and F, revision of their proposed structure, and their conversion to potent Hsp90 inhibitors.
Karthikeyan G; Zambaldo C; Barluenga S; Zoete V; Karplus M; Winssinger N
Chemistry; 2012 Jul; 18(29):8978-86. PubMed ID: 22696415
[TBL] [Abstract][Full Text] [Related]
23. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
Kumalo HM; Bhakat S; Soliman ME
Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
[TBL] [Abstract][Full Text] [Related]
24. Structural models and binding site prediction of the C-terminal domain of human Hsp90: a new target for anticancer drugs.
Sgobba M; Degliesposti G; Ferrari AM; Rastelli G
Chem Biol Drug Des; 2008 May; 71(5):420-433. PubMed ID: 18373550
[TBL] [Abstract][Full Text] [Related]
25. Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90.
Buchstaller HP; Eggenweiler HM; Sirrenberg C; Grädler U; Musil D; Hoppe E; Zimmermann A; Schwartz H; März J; Bomke J; Wegener A; Wolf M
Bioorg Med Chem Lett; 2012 Jul; 22(13):4396-403. PubMed ID: 22632933
[TBL] [Abstract][Full Text] [Related]
26. Targeting the Hsp90 C-terminal domain by the chemically accessible dihydropyrimidinone scaffold.
Strocchia M; Terracciano S; Chini MG; Vassallo A; Vaccaro MC; Dal Piaz F; Leone A; Riccio R; Bruno I; Bifulco G
Chem Commun (Camb); 2015 Mar; 51(18):3850-3. PubMed ID: 25656927
[TBL] [Abstract][Full Text] [Related]
27. Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.
Koay YC; Wahyudi H; McAlpine SR
Chemistry; 2016 Dec; 22(51):18572-18582. PubMed ID: 27859703
[TBL] [Abstract][Full Text] [Related]
28. Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone.
Kung PP; Sinnema PJ; Richardson P; Hickey MJ; Gajiwala KS; Wang F; Huang B; McClellan G; Wang J; Maegley K; Bergqvist S; Mehta PP; Kania R
Bioorg Med Chem Lett; 2011 Jun; 21(12):3557-62. PubMed ID: 21612924
[TBL] [Abstract][Full Text] [Related]
29. Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles.
Kreusch A; Han S; Brinker A; Zhou V; Choi HS; He Y; Lesley SA; Caldwell J; Gu XJ
Bioorg Med Chem Lett; 2005 Mar; 15(5):1475-8. PubMed ID: 15713410
[TBL] [Abstract][Full Text] [Related]
30. From a ratchet mechanism to random fluctuations evolution of Hsp90's mechanochemical cycle.
Ratzke C; Nguyen MN; Mayer MP; Hugel T
J Mol Biol; 2012 Oct; 423(3):462-71. PubMed ID: 22878379
[TBL] [Abstract][Full Text] [Related]
31. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation.
Goode KM; Petrov DP; Vickman RE; Crist SA; Pascuzzi PE; Ratliff TL; Davisson VJ; Hazbun TR
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1992-2006. PubMed ID: 28495207
[TBL] [Abstract][Full Text] [Related]
32. How well can fragments explore accessed chemical space? A case study from heat shock protein 90.
Roughley SD; Hubbard RE
J Med Chem; 2011 Jun; 54(12):3989-4005. PubMed ID: 21561141
[No Abstract] [Full Text] [Related]
33. Design and biological testing of peptidic dimerization inhibitors of human Hsp90 that target the C-terminal domain.
Bopp B; Ciglia E; Ouald-Chaib A; Groth G; Gohlke H; Jose J
Biochim Biophys Acta; 2016 Jun; 1860(6):1043-55. PubMed ID: 26774645
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel Hsp90 C-terminal domain inhibitors that disrupt co-chaperone binding.
Mak OW; Sharma N; Reynisson J; Leung IKH
Bioorg Med Chem Lett; 2021 Apr; 38():127857. PubMed ID: 33609661
[TBL] [Abstract][Full Text] [Related]
35. Fragment screening using capillary electrophoresis (CEfrag) for hit identification of heat shock protein 90 ATPase inhibitors.
Austin C; Pettit SN; Magnolo SK; Sanvoisin J; Chen W; Wood SP; Freeman LD; Pengelly RJ; Hughes DE
J Biomol Screen; 2012 Aug; 17(7):868-76. PubMed ID: 22573733
[TBL] [Abstract][Full Text] [Related]
36. Hsp90 inhibitors, part 1: definition of 3-D QSAutogrid/R models as a tool for virtual screening.
Ballante F; Caroli A; Wickersham RB; Ragno R
J Chem Inf Model; 2014 Mar; 54(3):956-69. PubMed ID: 24564321
[TBL] [Abstract][Full Text] [Related]
37. Discovery of a novel Hsp90 inhibitor by fragment linking.
Barker JJ; Barker O; Courtney SM; Gardiner M; Hesterkamp T; Ichihara O; Mather O; Montalbetti CA; Müller A; Varasi M; Whittaker M; Yarnold CJ
ChemMedChem; 2010 Oct; 5(10):1697-700. PubMed ID: 20665758
[No Abstract] [Full Text] [Related]
38. Elucidation of the Hsp90 C-terminal inhibitor binding site.
Matts RL; Dixit A; Peterson LB; Sun L; Voruganti S; Kalyanaraman P; Hartson SD; Verkhivker GM; Blagg BS
ACS Chem Biol; 2011 Aug; 6(8):800-7. PubMed ID: 21548602
[TBL] [Abstract][Full Text] [Related]
39. Prediction of inhibitory activities of Hsp90 inhibitors.
Swuec P; Barlow DJ
Bioorg Med Chem; 2012 Jan; 20(1):408-14. PubMed ID: 22112537
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors.
Neubert T; Numa M; Ernst J; Clemens J; Krenitsky P; Liu M; Fleck B; Woody L; Zuccola H; Stamos D
Bioorg Med Chem Lett; 2015 Mar; 25(6):1338-42. PubMed ID: 25677667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
